This would be transformative for physicians, patients, and their families. The company noted that FTD and ALS overlap genetically, clinically and pathologically, with approximately half of FTD patients manifesting cytoplasmic TDP-43 aggregates similar to those seen in ALS.Īn early and non-invasive diagnostic test that can detect the presence of TDP-43 aggregates in CNS tissue would greatly enhance diagnostic sensitivity and specificity of ALS and FTD, and aid in guiding therapy and assessing the state of disease pathogenesis in vivo at the molecular level. At a molecular level, the accumulation of cytoplasmic TDP-43 occurs in ~97% of ALS cases and is believed to play a role in disease pathogenesis. Currently, no definitive diagnostic technology is available for ALS and FTD. has announced a new Phase 1 grant award from the National Institute of Aging at the National Institutes of Health (NIH).Īccording to a news release from the company, the grant supports the development of a novel small-molecule retinal tracer targeting the biomarker TAR DNA-binding protein 43 (TDP-43) in patients with amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD).ĪLS is a neurodegenerative disease that can be challenging to diagnose due to clinical overlaps with other conditions.
0 kommentar(er)
